Nuveen’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $833K | Buy |
57,131
+4,861
| +9% | +$65.3K | ﹤0.01% | 3033 |
|
|
2026
Q1 | $660K | Sell |
52,270
-33,786
| -39% | -$453K | ﹤0.01% | 2744 |
|
|
2025
Q4 | $1.36M | Sell |
86,056
-78,704
| -48% | -$1000K | ﹤0.01% | 2463 |
|
|
2025
Q3 | $1.97M | Buy |
164,760
+119,875
| +267% | +$958K | ﹤0.01% | 2302 |
|
|
2025
Q2 | $339K | Sell |
44,885
-11,786
| -21% | -$70.9K | ﹤0.01% | 3000 |
|
|
2025
Q1 | $313K | Buy |
56,671
+1,064
| +2% | +$6.57K | ﹤0.01% | 3029 |
|
|
2024
Q4 | $320K | Hold |
55,607
| – | – | ﹤0.01% | 3114 |
|
|
2024
Q3 | $576K | Hold |
55,607
| – | – | ﹤0.01% | 2964 |
|
|
2024
Q2 | $721K | Sell |
55,607
-33,780
| -38% | -$456K | ﹤0.01% | 2859 |
|
|
2024
Q1 | $1.56M | Buy |
89,387
+33,780
| +61% | +$447K | ﹤0.01% | 2506 |
|
|
2023
Q4 | $523K | Buy |
55,607
+106
| +0.2% | +$988 | ﹤0.01% | 2985 |
|
|
2023
Q3 | $620K | Sell |
55,501
-595
| -1% | -$9.6K | ﹤0.01% | 2770 |
|
|
2023
Q2 | $1.2M | Hold |
56,096
| – | – | ﹤0.01% | 2578 |
|
|
2023
Q1 | $2.27M | Sell |
56,096
-5,284
| -9% | -$252K | ﹤0.01% | 2281 |
|
|
2022
Q4 | $2.86M | Sell |
61,380
-9,095
| -13% | -$415K | ﹤0.01% | 2226 |
|
|
2022
Q3 | $3.66M | Sell |
70,475
-1,543
| -2% | -$90.1K | ﹤0.01% | 2077 |
|
|
2022
Q2 | $3.4M | Sell |
72,018
-73,462
| -50% | -$3.99M | ﹤0.01% | 2168 |
|
|
2022
Q1 | $9.7M | Buy |
145,480
+49,322
| +51% | +$3.21M | ﹤0.01% | 1662 |
|
|
2021
Q4 | $6.4M | Buy |
96,158
+14,612
| +18% | +$1.15M | ﹤0.01% | 1967 |
|
|
2021
Q3 | $4.76M | Buy |
81,546
+390
| +0.5% | +$19.3K | ﹤0.01% | 2242 |
|
|
2021
Q2 | $3.57M | Sell |
81,156
-3,863
| -5% | -$189K | ﹤0.01% | 2416 |
|
|
2021
Q1 | $4.19M | Sell |
85,019
-2,454
| -3% | -$122K | ﹤0.01% | 2246 |
|
|
2020
Q4 | $3.68M | Sell |
87,473
-3,114
| -3% | -$137K | ﹤0.01% | 2223 |
|
|
2020
Q3 | $4.15M | Sell |
90,587
-21,527
| -19% | -$1.04M | ﹤0.01% | 2021 |
|
|
2020
Q2 | $5.63M | Buy |
112,114
+13,282
| +13% | +$687K | ﹤0.01% | 1831 |
|
|
2020
Q1 | $5.08M | Sell |
98,832
-18,819
| -16% | -$1M | ﹤0.01% | 1707 |
|
|
2019
Q4 | $7.27M | Sell |
117,651
-92,118
| -44% | -$5.71M | ﹤0.01% | 1778 |
|
|
2019
Q3 | $12.6M | Buy |
209,769
+12,018
| +6% | +$893K | 0.01% | 1416 |
|
|
2019
Q2 | $16.7M | Buy |
+197,751
| New | +$17.8M | 0.01% | 1267 |
|
Other funds holding ENTA
KAM
SSC
Nuveen's ENTA Position: Q2 2026 in Review
Nuveen increased its Enanta Pharmaceuticals (ENTA) stake by 9.3% in Q2 2026, buying an estimated $65.3K and bringing the position to 57,131 shares worth $833K. The position accounts for ﹤0.01% of the portfolio, ranked #3033.
Nuveen first reported a position in ENTA in Q2 2019 and has held it in 29 quarters since. The position peaked at $16.7M in Q2 2019. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.
- Nuveen held 57,131 shares of Enanta Pharmaceuticals worth $833K as of Q2 2026.
- Nuveen bought 4,861 Enanta Pharmaceuticals shares in Q2 2026, an estimated $65.3K.
- Enanta Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3033 holding.
- Nuveen first reported a position in Enanta Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
- Nuveen's Enanta Pharmaceuticals position peaked at $16.7M in Q2 2019.
- 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.